Abstract | BACKGROUND: PATIENTS AND METHODS: Embase, Medline and Cochrane databases were searched for included studies. Clinical trials published in English and utilising immune checkpoint blockade for primary tumours situated in the lower gastrointestinal tract were included. Databases were searched for studies reporting on at least one of overall survival, progression-free survival or response to therapy. RESULTS: CONCLUSIONS: A number of patients with advanced lower gastrointestinal tumours achieved a complete response to treatment for what would otherwise be considered palliative disease. Presented data have highlighted that particular patients may benefit from first-line or combination immunotherapy, and thus, further investigation is warranted to individualise treatment.
|
Authors | K C Wilson, M P Flood, D Oh, N Calvin, M Michael, R G Ramsay, A G Heriot |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 28
Issue 12
Pg. 7463-7473
(Nov 2021)
ISSN: 1534-4681 [Electronic] United States |
PMID | 34047860
(Publication Type: Journal Article, Systematic Review)
|
Copyright | © 2021. Society of Surgical Oncology. |
Chemical References |
- Immune Checkpoint Inhibitors
- Nivolumab
|
Topics |
- Gastrointestinal Neoplasms
(drug therapy)
- Humans
- Immune Checkpoint Inhibitors
- Immunotherapy
- Nivolumab
(therapeutic use)
- Progression-Free Survival
|